Ontology highlight
ABSTRACT: Introduction
The outcome of patients with CML who discontinue 2G-TKI initial therapy is unknown. We analyzed the characteristics of patients in whom treatment with first-line 2G-TKIs had failed.Patients and methods
A total of 218 patients with CML were treated with dasatinib (n = 101) or nilotinib (n = 117; 12 in AP). After a median follow-up of 23 months, 40 patients (18%) discontinued therapy: 25 initially treated with nilotinib (21% of all treated with nilotinib; 6 treated in AP) and 15 (15%) initially treated with dasatinib. Median age of the patients was 47 (range, 19-79) years, and they had received therapy for a median of 8 (range, 0-62) months.Results
Reasons for treatment discontinuation include: toxicity, 16 patients; resistance in CP, 5 patients; transfor
SUBMITTER: Eghtedar A
PROVIDER: S-EPMC3752280 | biostudies-literature | 2013 Aug
REPOSITORIES: biostudies-literature